The Skin Cancer Drugs Clinical Pipeline 2025​


​Release Date: Q1' 2025
Number of Candidates: 97

Synopsis: Skin cancer, the uncontrolled growth of abnormal skin cells, is among the most common types of cancer. With the exception of melanoma, most skin cancers are not life threatening. However, early diagnosis and treatment are critical to avoid functional or cosmetic deformities that can result from the invasion and damage of nearby tissues and organs. 

Although surgery is the most common treatment for skin cancer, drugs – including chemotherapy, immunotherapy and targeted agents – are widely used for treating advanced forms of skin cancer. Drug developers are investing heavily in new drug development programs for skin cancer, primarily in the areas of melanoma, BCC (Basal Cell Carcinoma) and SCC (Squamous Cell Carcinoma), with several promising candidates in the late stages of the clinical pipeline.
The “Skin Cancer Drugs Pipeline 2025” excel sheet presents a look at the major drug candidates currently in the clinical pipeline.

The data-set is delivered in an Excel sheet covering clinical drug development pipeline for the skin cancer drugs market, profiling 97 future candidates.

For a Sample and Inquiries please contact [email protected]

Pricing: The pipeline excel data sheet is available for the following price: 
​
Single User License: USD 800

Company Wide License (Single Site): USD 1,200

Company Wide License (Global Site): USD 2,000

Pipeline Candidates Data Segmentation:
Drug pipeline data set offers a breakdown in the following subcategories:
  • Candidate (Name)
  • Drug Developer(s)
  • Indication/Therapeutic Area(s)​
    • Actinic Keratosis
    • BCC (Basal Cell Carcinoma)
    • CTCL (Cutaneous T-Cell Lymphoma)
    • Kaposi's Sarcoma
    • MCC (Merkel Cell Carcinoma)
    • Melanoma
    • Multiple Skin Cancers
    • SCC (Squamous Cell Carcinoma)
    • Soft Tissue Sarcoma
  • Classification(s)
    • Combination Therapy
    • Gene & Cell Therapy
    • Monoclonal Antibody 
    • Small Molecule
    • Virus & Vaccine
    • Others
  • Phase
    • Pre-Clinical
    • ​Phase I
    • Phase I/II
    • Phase II
    • Phase II/III
    • Phase III
    • Pre-Registration​

List of Companies Mentioned:
The following companies and organizations have been mentioned in the pipeline:
AbbVie
Adaptimmune 
Agenus
Akeso Biopharma
Altor BioScience
Amgen
Angimmune
Ascend Biopharmaceuticals
AstraZeneca
Autotelic
Biodesix
Biogen
Bioniz
BioNTech
Biosceptre
Boehringer Ingelheim
BPGbio (Berg Pharma)
Bristol-Myers Squibb
Celldex Therapeutics
Celltrion
CEL-SCI Corporation
Checkmate Pharmaceuticals (Acquired by Regeneron)
Checkpoint Therapeutics
DermBiont
DFB Soria
Dr. Reddy’s Laboratories 
Eisai
Elevar Therapeutics (Previously LSK BioPharma)
Elios Therapeutics
Equillium (Bioniz) 
Eterna Therapeutics
Exelixis
Galectin Therapeutics
Genentech (Roche)
GSK (GlaxoSmithKline) 
Hanmi Pharmaceutical
HiberCell
Huya Bioscience
Immunocore
Innate Pharma
Innovent Biologics
Inovio Pharmaceutical
Iovance Biotherapeutics
Ipsen
Kintara Therapeutics
Kowa
Krystal Biotech
LadRx Corporation
Lumos Pharma (NewLink Genetics)
MedImmune (AstraZeneca)
Medivir
Merck & Co
Merck KGaA
Moderna
NanoCarrier
Nanology
NantCell
Neumedicines
Novartis
Oncolys Biopharma
Oncolytics Biotech
Oncotelic
Ono Pharmaceuticals
Pfizer
Philogen
Phio Pharmaceuticals
Photogen Technologies Inc.
Pierre Fabre
Polaris Pharmaceuticals
Polynoma
Privo Technologies
Provectus Biopharmaceuticals 
Pyxis Oncology
Regeneron Pharmaceutical
Replimune
Roche (Ignyta)
Sol-Gel Technologies
Soligenix
Summit Therapeutics
Takara Bio
Transgene
TriSalus Life Sciences
Ultimovacs
Vidac Pharma